Abstract：
Organ fibrosis is a devastating medical challenge that is collectively responsible for an estimated 45% of all deaths in developed countries and poses a substantial health and economic burden. The process of fibrosis has common characteristics that can occur in various organs, such as the liver, kidney, lung, and skin. Currently, there is a paucity of effective treatments available for fibrosis. Therefore, it is crucial to identify new approaches to find potential therapeutic targets. Genetic studies have shown great promise in advancing the drug development process. Mer tyrosine kinase (MERTK) was recently identified as a crucial regulator of fibrosis that specifically controls the activity of transforming growth factor beta (TGFβ). In this brief review, we provide an overview of the potential role of MERTK as a targeted and valuable approach for treating organ fibrosis.
摘要：
器官纤维化是一项毁灭性的医学挑战，在发达国家估计有45％的死亡是共同原因，并造成了巨大的健康和经济负担。纤维化的过程具有可以发生在各个器官中的共同特征，比如肝脏，肾,肺，和皮肤。目前,目前缺乏有效的纤维化治疗方法。因此,确定寻找潜在治疗靶点的新方法至关重要.遗传研究在推进药物开发过程中显示出巨大的希望。Mer酪氨酸激酶（MERTK）最近被确定为纤维化的关键调节剂，可特异性控制转化生长因子β（TGFβ）的活性。在这个简短的审查，我们概述了MERTK作为治疗器官纤维化的靶向和有价值的方法的潜在作用.
